Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET scan tracer could shine a light on hidden pancreatic tumors

NCT ID NCT07340437

Diagnosis Sponsor: Sichuan Provincial People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new radioactive tracer called 18F-Exendin-4, used with PET/CT scans, to see if it can better detect insulinoma—a rare tumor in the pancreas that causes dangerously low blood sugar. Twenty participants with confirmed insulinoma received the tracer and underwent imaging. The goal was to compare the scan results with standard tests like MRI and CT. If the new method proves accurate, it could offer a less invasive way to diagnose these tumors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
18F-Exendin-4 (a radioactive tracer for PET/CT imaging)
What this could lead to
If successful, this imaging method could provide a more accurate, non-invasive way to detect insulinoma, potentially reducing the need for exploratory surgery.
What could go wrong
This is a small, early-stage study with only 20 participants, so results may not apply to everyone. The probe's accuracy and safety need further validation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

20 people

The number who actually took part.

Started

Feb 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with diagnosed or highly suspected insulinoma.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * biochemically confirmed hyperinsulinemic hypoglycemia (plasma glucose \< 3.0 mmol/L, insulin \> 3 μIU/mL, C-peptide \> 0.6 ng/mL) * surgical or biopsy-confirmed insulinoma or non-insulinoma pancreatogenous hypoglycemia syndrome, with definitive clinical diagnosis at discharge and comprehensive evaluation for hypoglycemia etiology during hospitalization. Exclusion Criteria: * unknown etiology of hypoglycemia at last follow-up * patients clinically diagnosed with insulinoma but without subsequent surgical intervention or biopsy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Insulinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adult-onset non-insulinoma persistent hyperinsulinemic hypoglycemia pancreatic insulinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Insulinoma

Contacts and locations

Locations

  • Department of Endocrinology and Department of Nuclear Medicine, Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072

    Chengdu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.